Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01059617 · ClinicalTrials.gov registry record · Phase 1
Safety and Immune Response of Candidate H1N1 Influenza Vaccine GSK2340274A Following Seasonal Influenza Vaccination in Adults
A Phase 1 study, sponsored by GlaxoSmithKline.
- Completed
- Registry status
- Phase 1
- Development phase
- 133
- Enrollment target
NCT01059617 is a Phase 1 study that has completed, run by GlaxoSmithKline. The registered enrollment target is 133 participants.
The verdict
NCT01059617, a Phase 1 study, has completed, sponsored by GlaxoSmithKline.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 133 participants
- Enrollment target
Study Summary
This study is designed to characterize the safety and immunogenicity of a' pandemic influenza (H1N1) candidate vaccine GSK2340274A in adults 19 to 40 years who have never received influenza vaccination.
Interventions
- BIOLOGICAL GSK Biologicals' FluLaval®
- BIOLOGICAL Placebo (saline)
- BIOLOGICAL GSK Biologicals' investigational H1N1 Influenza Vaccine - GSK2340274A
- BIOLOGICAL GSK Biologicals' investigational H1N1 Influenza Vaccine - GSK2340273A
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 133 participants |
| Start Date | 2010-02-09 |
| Est. Completion | 2011-10-21 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01059617
The ClinicalTrials.gov registry entry for NCT01059617 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 133 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is GlaxoSmithKline, which has 1,345 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which GSK Biologicals' FluLaval® is the first listed.
NCT01059617 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01059617 about?
NCT01059617 is a clinical study titled "Safety and Immune Response of Candidate H1N1 Influenza Vaccine GSK2340274A Following Seasonal Influenza Vaccination in Adults". This study is designed to characterize the safety and immunogenicity of a' pandemic influenza (H1N1) candidate vaccine GSK2340274A in adults 19 to 40 years who have never received influenza vaccination.
What is the current status of trial NCT01059617?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 133 participants. The study started on 2010-02-09. Estimated completion is 2011-10-21.
What interventions are being tested in trial NCT01059617?
The interventions under investigation include: GSK Biologicals' FluLaval® (BIOLOGICAL), Placebo (saline) (BIOLOGICAL), GSK Biologicals' investigational H1N1 Influenza Vaccine - GSK2340274A (BIOLOGICAL), GSK Biologicals' investigational H1N1 Influenza Vaccine - GSK2340273A (BIOLOGICAL).
Who is sponsoring clinical trial NCT01059617?
This trial is sponsored by GlaxoSmithKline, which has 1,345 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.